A controlled trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer.

Montgomery, R. D.; Lawrence, Ira; Manton, David J.; Mendl, Karl; Rowe, Pamela

doi:10.1136/gut.9.6.704

Cited by 19 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings agree with those obtained by others who obtained evidence of symptomatic benefit (Craig et al, 1967) or endoscopic improvement (Archambault et al, 1975), and similar though statistically insignificant trends towards improvement were noted by others in terms of earlier endoscopic improvement (Brown et al, 1972) or radiological improvement (Montgomery et al, 1968). Our results show more convincing evidence of benefit to those receiving carbenoxolone capsules than has usually been obtained in the past, and this reflects the large number of patients who were studied as well as the reliance which we placed upon endoscopic criteria for assessment.…”

Section: Discussionsupporting

confidence: 92%

Carbenoxolone sodium capsules in the treatment of duodenal ulcer. An endoscopic controlled trial.

1977

Gut

View full text Add to dashboard Cite

SUMMARY Eighty-six patients with duodenal ulcer were treated in a multicentre controlled trial with carbenoxolone capsules (Duogastrone, 50 mg four times a day for six weeks)jor a placebo. Sixtynine patients accepted endoscopy at the beginning and end of the treatment. Symptomatic responses and endoscopic improvement were significantly greater in those receiving the active preparation than in those receiving the control capsules, complete, endoscopically assessed, healing being achieved in 65 % and 20 %, respectively, of individuals having accepted endoscopy, after six weeks' treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Carbenoxolone sodium capsules in the treatment of duodenal ulcer. An endoscopic controlled trial.

1977

Gut

View full text Add to dashboard Cite

show abstract

“…A pilot trial was carried out in 1967 in which the clinical results of the treatment (wiih Duogastrone) of Servicemen with duodenal ulceration were compared with a similar group of patients treated with propantheline bromide tablets (Cliff, 1968); the response to carbenoxolone sodium capsules was so satisfactory and confirmed by other preliminary studies (Craig, Hunt, Kimerling, and Parke, 1967;Hunt, 1968;Lawrence, Manton, Mendl, and Montgomery, 1968) that a double-blind controlled trial against placebo was set up. We now report our findings in 100 patients who have been followed up for six months.…”

mentioning

confidence: 84%

“…Fluid retention, hypertension, potassium loss, and heartburn can occur during the administration of carbenoxolone tablets (Biogastrone), especially in the presence of overt cardiac and renal disease (Turpie and Thomson, 1965) but the positioned-release capsules (Duogastrone) produced no such side effects in a group of 32 patients (Craig et al, 1967); in another series of 22 patients mild hypokalaemia and fluid retention was noted on two occasions (Montgomery,169 A douible-blind trial of carbenoxolone sodium capsules in the treatment ofduodenal ulcer Lawrence, Manton, Mendl, and Rowe, 1968) and one example of hypokalaemia with muscle paresis has been reported in a patient taking carbenoxolone 200 mg daily in the form of Duogastrone for a period of six weeks (Forshaw, 1969).…”

Section: Side Effectsmentioning

confidence: 99%

A double-blind trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer

Cliff¹,

Milton-Thompson²

1970

Gut

View full text Add to dashboard Cite

SUMMARY A controlled trial of carbenoxolone sodium positioned-release capsules (Duogastrone) was carried out on a randomized series of 100 unselected male Service personnel with symptoms of active duodenal ulceration and supporting radiological evidence. Fifty-seven patients completed the trial, 29 in the carbenoxolone group and 28 in the control group. The carbenoxolone group was given capsules containing 50 mg carbenoxolone four times a day for 12 weeks while the controls received a capsule identical in every respect except that it did not contain carbenoxolone. All patients were assessed at fortnightly intervals and had clinical and radiological reassessments three and six months after commencing treatment.Review at three months and at six months revealed a slight but clinically insignificant trend in favour of the carbenoxolone group.As a corollary to this controlled trial, those patients (38 in all) who did not have an early remission of symptoms were removed from the trial and placed on capsules known to contain carbenoxolone. Subsequently these patients did not show an advantage for carbenoxolone.Carbonexolone sodium has been shown in several controlled trials to increase the rate of healing of chronic gastric ulcers in the ambulant patient

show abstract

“…Furthermore, if carbenoxolone is absorbed when the drug is administered as the capsule, the mineralocorticoid side effects that occasionally occur when the drug is given orally as tablets might also occur when the capsule is given. In fact this has now been observed (Forshaw, 1969;Montgomery et al, 1968).…”

mentioning

confidence: 63%

The absorption of carbenoxolone administered orally as a positioned-release capsule

Lindup¹,

Parke²,

Colin‐Jones³

1970

Gut

View full text Add to dashboard Cite

A controlled trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer.

Cited by 19 publications

References 5 publications

Carbenoxolone sodium capsules in the treatment of duodenal ulcer. An endoscopic controlled trial.

Carbenoxolone sodium capsules in the treatment of duodenal ulcer. An endoscopic controlled trial.

A double-blind trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer

The absorption of carbenoxolone administered orally as a positioned-release capsule

Contact Info

Product

Resources

About